Nanosphere — Investor Day (June 2012)
58 slides from Nanosphere's investor day presentation, Jun 13, 2012
Slide 1: Investor Day, June 13, 2012
iN y__\ MBB investor Day Mmm ene 13, 2012
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements about us and our industry that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this presentation regarding our strategy, future operations, future fina
Slide 3: Fulfilling the Promise
Fulfilling the Promise Parallel Development Strategies Provide Clear Path to Profitability with Significant Upside to Value Creation Conversion of microbiology to molecular methods drives profitability and sustained growth Cardiovascular Diagnostics generates significant upside Nanosphere Becomes a
Slide 4: Need for Speed Drives Decentralization
Need for Speed Drives Decentralization Today 2015E $21.5B $24.9B $20.6B $29.3B Reference Labs (500) Hospital Labs (6,000 in total; 1,500 currently offer MDx) 10-15% Growth 5% Growth Over 4,500 hospital labs currently do not offer MDx but a majority of them plan to add MDx platforms in the next 3 yea
Slide 5: Positioned for Global MDx Leadership
Positioned for Global MDx Leadership Diagnostics Market - $41B (5-6%) Molecular Diagnostics - $4B (10-15%) Infectious Diseases Cardio/ Vascular Respiratory Viruses Blood Stream Infections Enteric Infections Troponin (heart attack & chronic heart failure) Thrombophilia Plavix and warfarin metabolism
Slide 6: U.S. Market Opportunity
U.S. Market Opportunity Immediate Market Access Conversion of Microbiology to Molecular Methods $ 760M ++ PLUS ++ ++ PLUS ++ Intermediate Market Development (3-5 years; market education) Intermediate Market Development (3-5 years; market education) Pharmacogenetics Ultra-sensitive cTnI for AMI rule-
Slide 7: MDx Decentralization Drivers
MDx Decentralization Drivers Product Feature Need Sample-To- Result Double- Digit- Plexing Decentralization (from reference labs to hospitals) Complex Disease Detection (10-30 targets per sample) Hospitals are taking sophisticated MDx capabilities in-house Hospitals' need for more timely and cost ef
Slide 8: Five Years Ago, Sample-To-Result MDx Enough To Establish Leadership
Five Years Ago, Sample-To-Result MDx Enough To Establish Leadership In Previously Untapped Market Five Years Ago Sample-to-result capability (in hospital labs) fueled the emergence of a major MDx market (MRSA screening) Note: Based upon Wall Street research and Nanosphere management estimates. Avail
Slide 9: Sample-To-Result With Double-Digit-Plexing Needed For Untapped Markets
Available Untapped Markets Available Untapped Markets Available Untapped Markets Ideal Number of "Plex" Global Market Size 15-30 $200M 10-15 $400M 20 $150M 10-15 $100M Today, Sample-To-Result WITH Double-Digit-Plexing Is Needed To Break Into The Untapped Markets Today Leadership in BSI, Enteric, Ext
Slide 10: Untapped BSI Market Validated by Other Attempts
Untapped BSI Market Validated by Other Attempts Now Penetrated by Nanosphere Launched in 2005 in Europe but has had very low sales due to: Lack of sample-to-result High-cost consumable 8-9 hour turnaround BSI collaboration started in '07; terminated in '10 due to insufficient technology for whole bl
Slide 11: Cepheid Success Demonstrates Potential
Cepheid Success Demonstrates Potential
Slide 12: Michael McGarrity, Chief Commercial Officer
Michael McGarrity Chief Commercial Officer
Slide 13: Fulfilling the Promise
Fulfilling the Promise BSI Addresses Clinical and Economic Problem Verigene Enables any Microbiology Lab Complex Requirements = Barriers to Entry Nanosphere Competitive Advantage Well Defined Commercial Plan Under Way
Slide 14: Acute and Growing Problem
Acute and Growing Problem Source: Ly, et al., Therapeutics and Clinical Risk Management, Jun 2008, 4(3):637- 640 and Elixhauser, et al, AHRQ, Statistical Brief #122, Oct 2011. Cost BSI is the most costly reason for U.S. inpatient hospitalization ($15.4B annual) Delayed Diagnosis & intervention As ea
Slide 15: Microbiology Test Requirements
Microbiology Test Requirements Multiplexed Multiple Infectious target identification & resistance Clinically Actionable Result Accurate >95% sensitivity >95% specificity Fast Rapid Turn Around Time Easy to Use Sample to Result On Demand - Random Access
Slide 16: Verigene Changes the Game
Verigene Changes the Game t=0 t=0 t=10 t=8h t=8h t=24-36h t=48-72h Bottle Culture Gram Stain Samples Plated for Sub-culturing Resistance Testing Bottle Culture Gram Stain BC- GP Blood Drawn Blood Drawn The Verigene Difference Saved Time, Money, Lives Current Blood Culture Workflow
Slide 17: Verigene Changes the Game
Verigene Changes the Game * Source: Ly, et al., Therapeutics and Clinical Risk Management, Jun 2008, 4(3):637-640 and Elixhauser, et al, AHRQ, Statistical Brief #122, Oct 2011. Saves Money Rapid reporting leads to 6.2 day reduction in length of stay $21,387 reduction in cost/patient False positives
Slide 18: Competitive Landscape: Nanosphere Emerges as Leader
Filter Double Digit- Plexing Filtering Competitive Landscape Nanosphere Emerges as Leader Multi-Plexed Targets Multi-Plexed Targets >200 >200 >200 100 50 25 <5 <5 <5 Note: Based upon Wall Street research and Nanosphere management estimates. Filter Decentralized Hospital Market- Ready Filter Position
Slide 19: Global Commercial Strategy
Global Commercial Strategy U.S. Direct Sales force System engineering support group Clinical applications group Customer service / operations Europe Distribution Thermo Fisher / Grifols Asia/Pacific Handock
Slide 20: Customer Focus
Customer Focus Regional Reference Labs with Limited Test Menu National Full-Service Reference Labs 35,000+ Clinics, Physician Offices / Other Laboratories ~4,500 Labs not Offering MDx Target customers: number of locations - US only
Slide 21: Established Customer Pipeline
Established Customer Pipeline
Slide 22: Fulfilling the Promise
Fulfilling the Promise Nanosphere leading conversion of outdated culture methods Immediate, well defined and understood Value Proposition Commercial organization already delivering on promise
Slide 23: Nathan A. Ledeboer
Nathan A. Ledeboer
Slide 24: Current blood culture timeline
6-18 hours Notification of ordering MD of positive culture and plate for ID and Sus After 12-14 h incubation (24-48 h from time of draw), bacteria grow, lab begins ID After 2-24 h ID ( 48 h total) is reported to MD via chart, 48-72 h from time of draw, full ID and susceptibility reported to MD
Slide 25: What about the Patient?
What about the Patient? Better Turn Around Could result in de-escalation of therapy faster A significant potential cost savings Could discontinue therapy for contaminants faster Less risk for adverse event Direct Identification from Positive Blood Cultures Current research developing protocols for d
Slide 26: Patient Impact
Patient Impact Retrospective chart review of patients with positive blood cultures obtained during validation a direct detection from positive blood culture bottles technology Time to ID (direct vs traditional culture methods) and start/stop times of antibiotics reviewed Theoretical reduction in emp
Slide 27: Time to Antimicrobial De-Escalation
Time to Antimicrobial De-Escalation Traditional ID Direct ID Difference (in hours) P Emperic Antibiotic Duration ( IQR, hrs) 66.6 (44.4-87.5) 15.5 (1.4-21.3) 51.6 (41.8-71.6) <0.01 Antibiotic Cost (USD) $245.24 $88.48 $156.76 <0.01 Paul J., et al. IDSA. 2011
Slide 28: Gram-Positive Blood Culture (BC-GP) Test
Gram-Positive Blood Culture (BC-GP) Test (CE-IVD) Gram-Positive Blood Culture (BC-GP) Test (CE-IVD) Gram-Positive Blood Culture (BC-GP) Test (CE-IVD) Gram-Positive Blood Culture (BC-GP) Test (CE-IVD) Genus Staphylococcus spp. Species Staphylococcus aureus Staphylococcus epidermidis Staphylococcus lu
Slide 29: Bacterial Targets
Bacterial Targets Culture Positive True Positive False Positive True Negative False Negative Sensitivity (CI) Specificity (CI) Staphylococcus spp. 83a 83 0 31 0 100 (95-100) 100 (88-100) S. aureus 35 35 0 79 0 100 (90-100) 100 (95-100) S. epidermidis 33 31 0 81 2b 93.9 (79-99) 100 (95-100) S. lugdun
Slide 30: Verigene Performance: Resistance Determinants
Verigene Performance Resistance Determinants Culture Positivea Sensitivity (CI) Specificity (CI) mecAb 35 97.1 (85-99) 97.0 (84-99) vanA/vanBc 3 66.7 (9-99) 100 (69-100)
Slide 31: US Enteric Panel
US Enteric Panel US Enteric Panel Bacteria Aeromonas spp. Bacteria Campylobacter spp. Bacteria Pleisomonas spp. Bacteria Salmonella spp. Bacteria Shigella spp. Bacteria Vibrio spp. Bacteria Yersinia spp. Bacteria Salmonella typhi Bacteria Shigella dysenteriae Bacteria Campylobacter jejuni Bacteria V
Slide 32: Conclusions
Conclusions Demands on the microbiology laboratory continues to evolve, placing increased emphasis on rapid, accurate testing systems. Multiplexed testing offers the potential to develop disease state testing as opposed to requiring physicians to request testing for each pathogen Random access testi
Slide 33: Roger Moody, Chief Financial Officer
Roger Moody Chief Financial Officer
Slide 34: Financial Overview
Financial Overview Investments to date provide significant financial leverage Microbiology opportunity alone drives to profitability and beyond Manufacturing poised for growth and highly scalable Future capital needs are very manageable
Slide 35: Building Sustainable Cash Flow
35 Building Sustainable Cash Flow RV BSI Gram+ C. Diff Enteric Clear Path To Low Cost Consumables BSI Gram- Working Capital
Slide 36: Microbiology Pipeline Drives Nanosphere to Profitability
Microbiology Pipeline Drives Nanosphere to Profitability
Slide 37: Clear Path to Cost Advantage
Clear Path to Cost Advantage Cartridge Total Substrate Plastic Components Labor / Overhead Reagents Cents per target for Double-Digit-Plexing tests Today Near Term At Scale $20 <$11 <$5 $9 <$4 <$1 $4 <$2 <$1
Slide 38: Gross Margin Scalability ~ Profitability
Gross Margin Scalability ~ Profitability
Slide 39: A Clear Path to Profitability
A Clear Path to Profitability
Slide 40: Potential Capital Requirement
Potential Capital Requirement Cash On Hand Working Capital Remaining Equipment Lease A/R LOC Solutions
Slide 41: Scalable Consumable Manufacturing
Scalable Consumable Manufacturing Batch processes Add Labor Spin Coating Step & Repeat Piezoelectric nano-plotters Step & Repeat or Continuous Flow Mostly Automated Complete Automation Step & Repeat Mostly Automated Complete Automation Step & Repeat Significant capacity with a small team capable of
Slide 42: Cardio Diagnostics Provides Significant Upside
Cardio Diagnostics Provides Significant Upside
Slide 43: Key Take Aways
Key Take Aways Investments to date provide significant financial leverage Microbiology opportunity alone drives to profitability and beyond Manufacturing poised for growth and highly scalable Future capital needs are very manageable
Slide 44: Redefining the Detection Limits for Molecular Diagnostic Tools
Redefining the Detection Limits for Molecular Diagnostic Tools and Enabling Point-of-Care Medicine June 2012 Chad A. Mirkin Director, International Institute for Nanotechnology, Northwestern University
Slide 45: Molecular Diagnostics: The Challenges
Molecular Diagnostics: The Challenges GENETIC MARKERS PCR/Fluorescence High Sensitivity Large Offsite Cumbersome Systems High Cost/High Skill Requirements Challenged with Respect to Multiplexing and Target Size Environmentally Challenged IMMUNO ASSAYS ELISA Low Sensitivity Inexpensive Challenged wit
Slide 46: Nanosphere technology: high sensitivity, massive multiplexing
The Nanosphere technology allows for high sensitivity, high selectivity detection, with massive multiplexing capabilities, regardless of target type or length. This opens up point-of-care applications and unique capabilities in point-of-care detection of DNA, and powerful new methods for the detecti
Slide 47: Spherical Nucleic Acids (SNAs)
Spherical Nucleic Acids (SNAs) 13 nm Au NP ~67,500 atoms Fluorescein 37 atoms 1 nm 40-mer Oligonucleotide 1400 atoms Synthetically Programmable Recognition Multivalency and Multi- functionality New Properties: Cooperative binding, Catalysis Mirkin et al, Nature 1996 (382) 607-609
Slide 48: What Makes SNA Particle Probes Unique?
SNAs: What SNA Particle Probes Makes Unique? Property Spherical Nucleic Acid Probess Linear Nucleic Acids Melting Transition Narrow (~1oC) Broad (~20oC) Binding Strength 100 x stronger Inorganic Core's Colorimetric, Catalytic, Magnetic, Fluorescent N/A A portfolio of over 290 patents covering SNA pa
Slide 49: Nanosphere Verigene System: Capabilities
Nanosphere Verigene System: Capabilities Clinical Microbiology Tests: - Influenza A and B* - Staphylococcus aureus* - 2009 H1N1* - Listeria spp. - Acinetobacter spp. Cardiac Tests: - Warfarin Metabolism* - F5/F2/MTHFR* Human Genetic Tests Pharmacogenetic Tests *FDA Cleared Panel Assays
Slide 50: Circulating MicroRNAs as New Targets for Molecular Diagnostics
Circulating MicroRNAs as New Targets for Molecular Diagnostics Short oligonucleotides that cannot be amplified by PCR At low concentrations in blood Over 1000 different types Different ones are deregulated as a function of disease state; SNPs make a difference Need profiling to determine which ones
Slide 51: MicroRNAs as Alternative Biomarkers for Prostate Cancer
MicroRNAs (miRNAs) as Alternative Biomarkers for Prostate Cancer Short (19-22 nucleotides) non- protein coding sequences Regulate the expression of 30-80% of all human protein-coding genes miRNA are found in stable form in blood and tissue Boyd. Laboratory Investigation, 2008; Mitchell et. al. PNAS,
Slide 52: Massive Multiplexing Allows Serum miRNA Detection
Massive Multiplexing Capabilities and Ability to Detect Short Targets Allow for Serum miRNA Detection (Invitrogen Array, ~1000 targets probed) (Invitrogen Array, ~1000 targets probed) (Invitrogen Array, ~1000 targets probed) (Invitrogen Array, ~1000 targets probed) Low signal Intensity High signal I
Slide 53: Summary of miRNAs Screened for Prostate Cancer
Payoff: Summary of miRNAs Screened with Nanosphere Technology for Gleason Score 9 Prostate Cancer (aggressive) Versus Gleason Score 6 (indolent) 1070 miRNAs screened 706 Validated 364 Novel 163 86
Slide 54: Field Defining Technologies
Field Defining Technologies
Slide 55: One Platform: Massive IP Portfolio and Many Detection Methods
DNA target Colorimetric Tests Simple, POC Silver-Amplification Commercialized, POC Uses miRNA Profiling miRNA Profiling Electrical Handheld Raman Massive Multiplexing, Dual Readout Bio-Barcode Assay Ultrahigh Sensitivity Protein Detection: New Markers/ Tests One Platform: Massive IP Portfolio and Ma
Slide 56: Slide 56
Slide 57: Investment Opportunity
Investment Opportunity Nanosphere at the inflection point Immediate market opportunity Right technology at right time Clear path to profitability Significant upside beyond microbiology Commercial growth expands capital opportunities Past investments create real leverage
Slide 58: Slide 58